Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Orally Administrated JBM-TC4 for the Prevention of Acute Radiation-induced Dermatitis in Breast Cancer Patients

NCT02289365 is registered in ClinicalTrials.gov with Joben Bio-Medical Co., Ltd. as lead sponsor.

NCT NCT02289365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02289365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Orally Administrated JBM-TC4 for the Prevention of Acute Radiation-induced Dermatitis in Breast Cancer Patients
Lead sponsor
Joben Bio-Medical Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2014
Completion date
December 31, 2016
Enrollment
120 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

radiodermatitis